$1.87
+0.53%Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Chief Executive Officer, President & Director
Compensation
$753,420
Chief Scientific Officer
Counsel
Interim Chief Financial Officer & Principal Accounting Officer
Vice President of Finance and Corporate Controller
During the last 12 months, insiders have purchased $544K worth of RNTX shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
405.4K
544.43K
0
0.00
+544K
+$544K
0
0.00
0
0.00
+0
+$0
Voss Capital, Lp
10 Percent Owner
$544K
No selling activity
Strong bullish signal with $544K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
RNTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | May 12, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 09, 2024 | August 20, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | January 29, 2024 | February 28, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 19, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 21, 2018 | 2018 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.